Pfizer Inc. (PFE) reported its Q2 financial results before the market open in the US on Thursday. World’s third largest pharmaceutical company topped both revenue and earnings per share estimates for the quarter. The company reported revenue of $27.742 billion in Q2 (up 47% year-over-year) vs. $25.487 billion expected.
Earnings per share reported at $2.04 per share (up by 92% year-over-year) vs. $1.72 per share estimate. Dr. Albert Bourla, Chairman and CEO commented on the latest results: ''In multiple meaningful ways, we made significant progress this quarter on our strategies to bring value to our patients and shareholders, while also making commitments to prioritize the broader needs of the world, including those of the environment and our most vulnerable populations.
For example, we set an ambitious goal for ourselves to achieve the Net-Zero Standard for greenhouse gas emissions by 2040, ten years ahead of the timeline described in the standard. We also launched an initiative to help bring all of our current and future patented medicines and vaccines to the 1.2 billion people living in 45 lower-income countries around the world at not-for-profit prices, a first in the industry.'' ''Even while launching these initiatives to support a healthier, more equitable world, we remain equally committed to strong financial execution on behalf of our shareholders. In the second quarter, we recorded the largest amount of quarterly sales in our history.
We also presented potentially best-in-class data for etrasimod and announced the proposed strategic acquisition of Biohaven, both of which are closely tied to our purpose: Breakthroughs that change patients’ lives,'' Dr. Bourla concluded. Pfizer Inc. (PFE) chart Despite beating Wall Street expectations for Q2, shares of Pfizer were down by around 1% at $50.98 per share.
Here is how the stock has performed in the past year: 1 Month -2.82% 3 Month +0.87% Year-to-date -13.72% 1 Year +19.07% Pfizer price targets Morgan Stanley $49 Wells Fargo $55 Citigroup $57 B of A Securities $70 Goldman Sachs $51 Pfizer Inc. is the 27 th largest company in the world with a market cap of $285.76 billion. You can trade Pfizer Inc. (PFE) and many other stocks from the NYSE, NASDAQ, HKEX and the ASX with GO Markets as a Share CFD. Sources: Pfizer Inc., TradingView, MetaTrader 5, Benzinga, CompaniesMarketCap
By
Klavs Valters
Account Manager, GO Markets London.
The information provided is of general nature only and does not take into account your personal objectives, financial situations or needs. Before acting on any information provided, you should consider whether the information is suitable for you and your personal circumstances and if necessary, seek appropriate professional advice. All opinions, conclusions, forecasts or recommendations are reasonably held at the time of compilation but are subject to change without notice. Past performance is not an indication of future performance. Go Markets Pty Ltd, ABN 85 081 864 039, AFSL 254963 is a CFD issuer, and trading carries significant risks and is not suitable for everyone. You do not own or have any interest in the rights to the underlying assets. You should consider the appropriateness by reviewing our TMD, FSG, PDS and other CFD legal documents to ensure you understand the risks before you invest in CFDs.
Tuesday, 12 May 2026, at roughly 7:30 pm AEST, Treasurer Jim Chalmers will stand up in Canberra and deliver the 2026-27 Federal Budget. According to Budget.gov.au, that is when the Budget is officially released, with the Budget papers going live online at the same time.
市場對頂尖製程晶圓及先進封裝(Advanced Packaging)的瘋狂胃納,其增長速度早已遠遠超越了全球供應鏈所能溫和承受的極限。這種極端的供需失衡,正強行逼迫各大 AI 龍頭大廠積極評估「第二供貨源(Second-source)」—— 呢點要稍為校準:這並不代表大廠們正在拋棄台積電,而是他們在實戰中迫切需要多一條通往大規模量產的備用防線。
支撐英特爾未來繼續狂飆的牛市邏輯非常直觀:**全球 AI 算力需求依舊極其瘋狂**,台積電的產能死鎖在短期內根本無法解開,這倒逼跨國科技巨頭必須不計代價尋求具備實質技術公信力的第二代工防線。如果英特爾能成功將目前的秘密測試與意向訂單逐步轉化為實質性的商業產出,全球長線資金將繼續為其晶圓代工戰略瘋狂計價。
最後,不容忽視的是更宏觀的 **AI 資本開支大週期**。一旦 Google、微軟、亞馬遜和 Meta 等超大規模雲端商(Hyperscalers)未來在龐大的基礎設施投入上放緩步伐、或是 AI 商業化變現的投資回報率(ROI)不如預期,成個半導體板塊都將迎來泥沙俱下的結構性大回撤,無論英特爾 Foundry 的製程進展得幾咁完美也無法獨善其身。
綜上所述,主導接下來外匯與股票交叉盤生死的黃金變數包括:輝達會否發出實質生產訂單、18A 工藝的最新良率進展、英特爾代工業務的虧損限度、台積電先進封裝擴產速度,以及北美雲端巨頭們的 AI 資本開支是否依舊強悍。